Silence Therapeutics plc (NASDAQ:SLN) Stock Position Raised by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in Silence Therapeutics plc (NASDAQ:SLN) by 609.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,092 shares of the company’s stock after acquiring an additional 5,233 shares during the quarter. GAMMA Investing LLC’s holdings in Silence Therapeutics were worth $42,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in SLN. Eventide Asset Management LLC acquired a new position in Silence Therapeutics in the 3rd quarter valued at approximately $11,635,000. Millennium Management LLC increased its stake in Silence Therapeutics by 91.2% in the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after buying an additional 373,523 shares during the period. Point72 Asset Management L.P. increased its stake in Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after buying an additional 321,300 shares during the period. Janus Henderson Group PLC increased its stake in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Finally, Parkman Healthcare Partners LLC increased its stake in Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Trading Down 1.5 %

NASDAQ:SLN opened at $5.90 on Tuesday. Silence Therapeutics plc has a 1 year low of $5.61 and a 1 year high of $27.72. The firm’s fifty day simple moving average is $8.83 and its 200 day simple moving average is $15.12. The firm has a market capitalization of $176.58 million, a PE ratio of -3.76 and a beta of 1.08.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on SLN shares. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Monday, December 9th. Chardan Capital restated a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Silence Therapeutics has a consensus rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.